PBYI vs. GALT, IVA, CAPR, VERU, OGI, ATOS, OMER, ZVRA, TRVI, and CDT
Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Galectin Therapeutics (GALT), Inventiva (IVA), Capricor Therapeutics (CAPR), Veru (VERU), Organigram (OGI), Atossa Therapeutics (ATOS), Omeros (OMER), Zevra Therapeutics (ZVRA), Trevi Therapeutics (TRVI), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical preparations" industry.
Puma Biotechnology (NASDAQ:PBYI) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.
Puma Biotechnology presently has a consensus target price of $7.00, suggesting a potential upside of 74.13%. Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 290.07%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than Puma Biotechnology.
In the previous week, Puma Biotechnology had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 5 mentions for Puma Biotechnology and 3 mentions for Galectin Therapeutics. Puma Biotechnology's average media sentiment score of 0.68 beat Galectin Therapeutics' score of 0.55 indicating that Puma Biotechnology is being referred to more favorably in the media.
61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 23.7% of Puma Biotechnology shares are held by insiders. Comparatively, 52.7% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Puma Biotechnology received 192 more outperform votes than Galectin Therapeutics when rated by MarketBeat users. Likewise, 66.54% of users gave Puma Biotechnology an outperform vote while only 60.10% of users gave Galectin Therapeutics an outperform vote.
Puma Biotechnology has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Puma Biotechnology has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
Puma Biotechnology has a net margin of 6.79% compared to Galectin Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 35.49% beat Galectin Therapeutics' return on equity.
Summary
Puma Biotechnology beats Galectin Therapeutics on 13 of the 15 factors compared between the two stocks.
Get Puma Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Puma Biotechnology Competitors List
Related Companies and Tools
